Beyond the Scavenging of Reactive Oxygen Species (ROS): Direct Effect of Cerium Oxide Nanoparticles in Reducing Fatty Acids Content in an In Vitro Model of Hepatocellular Steatosis
Abstract
:1. Introduction
2. Materials and Methods
2.1. Synthesis and Characterization of CeO2NPs
2.1.1. Synthesis
2.1.2. Albumin Conjugation
2.1.3. Characterization
2.2. Cell Culture
2.3. Internalization of CeO2NPs in HepG2 Cells
2.4. Cell Viability Analysis
2.5. Reactive Oxygen Species Measurement
2.6. Oxysterols Measurements
2.7. Induction of Steatosis in HepG2 Cells with Oleic and Palmitic Acids
2.8. Total FA Measurements
2.9. Statistical Analysis
3. Results
3.1. Characterization of CeO2NPs
3.2. Cellular Uptake of CeO2NPs
3.3. Effect of CeO2NPs in the Viability of HepG2 Incubated with H2O2
3.4. Effect of CeO2NPs in the ROS Production of HepG2 Incubated with H2O2
3.5. Effect of CeO2NPs in Cholesterol and Oxysterols Content of HepG2 Cells Treated with H2O2
3.6. Effects of CeO2NPs in Total FA Content of HepG2 Cells Treated with Oleic and Palmitic Acid
3.7. CeO2NPs Induce Specific Changes in the FA Metabolism of Steatotic HepG2 Cells
4. Discussion
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Acknowledgments
Conflicts of Interest
References
- Friedman, S.L.; Neuschwander-Tetri, B.A.; Rinella, M.; Sanyal, A.J. Mechanisms of NAFLD development and therapeutic strategies. Nat. Med. 2018, 24, 908–922. [Google Scholar] [CrossRef] [PubMed]
- Buzzetti, E.; Pinzani, M.; Tsochatzis, E.A. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). Metabolism 2016, 65, 1038–1048. [Google Scholar] [CrossRef] [PubMed]
- Italian Association for the Study of the Liver (AISF). AISF position paper on nonalcoholic fatty liver disease (NAFLD): Updates and future directions. Dig. Liver Dis. 2017, 49, 471–483. [Google Scholar] [CrossRef] [PubMed]
- Duvnjak, M.; Lerotić, I.; Baršić, I.; Tomašić, V.; Jukić, L.V.; Velagić, V. Pathogenesis and management issues for non-alcoholic fatty liver disease. World J. Gastroenterol. 2007, 13, 4539–4550. [Google Scholar] [CrossRef] [PubMed]
- Moore, J.B. From sugar to liver fat and public health: Systems biology driven studies in understanding non-alcoholic fatty liver disease pathogenesis. Proc. Nutr. Soc. 2019, 78, 290–304. [Google Scholar] [CrossRef] [PubMed]
- Bellanti, F.; Villani, R.; Facciorusso, A.; Vendemiale, G.; Serviddio, G. Lipid oxidation products in the pathogenesis of non-alcoholic steatohepatitis. Free Radic. Biol. Med. 2017, 111, 173–185. [Google Scholar] [CrossRef] [PubMed]
- Bellanti, F.; Villani, R.; Tamborra, R.; Blonda, M.; Iannelli, G.; di Bello, G.; Facciorusso, A.; Poli, G.; Iuliano, L.; Avolio, C.; et al. Synergistic interaction of fatty acids and oxysterols impairs mitochondrial function and limits liver adaptation during nafld progression. Redox Biol. 2018, 15, 86–96. [Google Scholar] [CrossRef] [PubMed]
- Singh, S.; Osna, A.N.; Kharbanda, K.K. Treatment options for alcoholic and non-alcoholic fatty liver disease: A review. World J. Gastroenterol. 2017, 23, 6549–6570. [Google Scholar] [CrossRef]
- Chalasani, N.; Younossi, Z.; Lavine, J.E.; Charlton, M.; Cusi, K.; Rinella, M.; Harrison, S.A.; Brunt, E.M.; Sanyal, A.J. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology 2018, 67, 328–357. [Google Scholar] [CrossRef]
- European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease. J. Hepatol. 2016, 64, 1388–1402. [Google Scholar] [CrossRef]
- Schubert, D.; Dargusch, R.; Raitano, J.; Chan, S.W. Cerium and yttrium oxide nanoparticles are neuroprotective. Biochem. Biophys. Res. Commun. 2006, 342, 86–91. [Google Scholar] [CrossRef] [PubMed]
- Karakoti, A.; Singh, S.; Dowding, J.M.; Seal, S.; Self, W.T. Redox-active radical scavenging nanomaterials. Chem. Soc. Rev. 2010, 39, 4422. [Google Scholar] [CrossRef] [PubMed]
- Nelson, B.C.; Johnson, M.E.; Walker, M.L.; Riley, K.R.; Sims, C.M. Antioxidant Cerium Oxide Nanoparticles in Biology and Medicine. Antioxidants 2016, 5, 15. [Google Scholar] [CrossRef] [PubMed]
- Xue, Y.; Zhai, Y.; Zhou, K.; Wang, L.; Tan, H.; Luan, Q.; Yao, X. The Vital Role of Buffer Anions in the Antioxidant Activity of CeO2Nanoparticles. Chem. A Eur. J. 2012, 18, 11115–11122. [Google Scholar] [CrossRef] [PubMed]
- Pagliari, F.; Mandoli, C.; Forte, G.; Magnani, E.; Pagliari, S.; Nardone, G.; Licoccia, S.; Minieri, M.; Di Nardo, P.; Traversa, E. Cerium Oxide Nanoparticles Protect Cardiac Progenitor Cells from Oxidative Stress. ACS Nano 2012, 6, 3767–3775. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ribera, J.; Rodríguez-Vita, J.; Cordoba, B.; Portolés, I.; Casals, G.; Casals, E.; Jiménez, W.; Puntes, V.; Morales-Ruiz, M. Functionalized cerium oxide nanoparticles mitigate the oxidative stress and pro-inflammatory activity associated to the portal vein endothelium of cirrhotic rats. PLoS ONE 2019, 14, e0218716. [Google Scholar] [CrossRef]
- Xu, C.; Qu, X. Cerium oxide nanoparticle: A remarkably versatile rare earth nanomaterial for biological applications. NPG Asia Mater. 2014, 6, e90. [Google Scholar] [CrossRef]
- Korsvik, C.; Patil, S.; Seal, S.; Self, W.T. Superoxide dismutase mimetic properties exhibited by vacancy engineered ceria nanoparticles. Chem. Commun. 2007, 14, 1056. [Google Scholar] [CrossRef]
- Pirmohamed, T.; Dowding, J.M.; Singh, S.; Wasserman, B.; Heckert, E.; Karakoti, A.S.; King, J.E.S.; Seal, S.; Self, W.T. Nanoceria exhibit redox state-dependent catalase mimetic activity. Chem. Commun. 2010, 46, 2736–2738. [Google Scholar] [CrossRef] [Green Version]
- Heckert, E.G.; Seal, S.; Self, W.T. Fenton-Like Reaction Catalyzed by the Rare Earth Inner Transition Metal Cerium. Environ. Sci. Technol. 2008, 42, 5014–5019. [Google Scholar] [CrossRef] [Green Version]
- Das, S.; Dowding, J.M.; Klump, E.K.; McGinnis, J.F.; Self, W.; Seal, S. Cerium oxide nanoparticles: Applications and prospects in nanomedicine. Nanomedicine (Lond.) 2013, 8, 1483–1508. [Google Scholar] [CrossRef] [PubMed]
- Niu, J.; Wang, K.; Kolattukudy, P.E. Cerium oxide nanoparticles inhibits oxidative stress and nuclear factor-kB activation in H9c2 cardiomyocytes exposed to cigarette smoke extract. J. Pharmacol. Exp. Ther. 2011, 338, 53–61. [Google Scholar] [CrossRef] [PubMed]
- Corsi, F.; Caputo, F.; Traversa, E.; Ghibelli, L. Not Only Redox: The Multifaceted Activity of Cerium Oxide Nanoparticles in Cancer Prevention and Therapy. Front. Oncol. 2018, 8, 309. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kargozar, S.; Baino, F.; Hoseini, S.J.; Hamzehlou, S.; Darroudi, M.; Verdi, J.; Hasanzadeh, L.; Kim, H.W.; Mozafari, M. Biomedical applications of nanoceria: New roles for an old player. Nanomedicine (Lond.) 2018, 13, 3051–3069. [Google Scholar] [CrossRef] [PubMed]
- Charbgoo, F.; Bin Ahmad, M.; Darroudi, M. Cerium oxide nanoparticles: Green synthesis and biological applications. Int. J. Nanomed. 2017, 12, 1401–1413. [Google Scholar] [CrossRef] [PubMed]
- Heckman, K.L.; DeCoteau, W.; Estévez, A.; Reed, K.J.; Costanzo, W.; Sanford, D.; Leiter, J.C.; Clauss, J.; Knapp, K.; Gómez, C.; et al. Custom Cerium Oxide Nanoparticles Protect against a Free Radical Mediated Autoimmune Degenerative Disease in the Brain. ACS Nano 2013, 7, 10582–10596. [Google Scholar] [CrossRef] [PubMed]
- Oró, D.; Yudina, T.; Fernández-Varo, G.; Casals, E.; Reichenbach, V.; Casals, G.; De La Presa, B.G.; Sandalinas, S.; Carvajal, S.; Puntes, V.; et al. Cerium oxide nanoparticles reduce steatosis, portal hypertension and display anti-inflammatory properties in rats with liver fibrosis. J. Hepatol. 2016, 64, 691–698. [Google Scholar] [CrossRef] [PubMed]
- Kobyliak, N.; Virchenko, O.; Falalyeyeva, T.; Kondro, M.; Beregova, T.; Bodnar, P.; Shcherbakov, O.; Bubnov, R.; Caprnda, M.; Delev, D.; et al. Cerium dioxide nanoparticles possess anti-inflammatory properties in the conditions of the obesity-associated NAFLD in rats. Biomed. Pharmacother. 2017, 90, 608–614. [Google Scholar] [CrossRef]
- Casals, E.; Gusta, M.F.; Piella, J.; Casals, G.; Jiménez, W.; Puntes, V. Intrinsic and Extrinsic Properties Affecting Innate Immune Responses to Nanoparticles: The Case of Cerium Oxide. Front. Immunol. 2017, 8, 970. [Google Scholar] [CrossRef]
- Gomez-Lechon, M.J.; Donato, M.T.; Martínez-Romero, A.; Jiménez, N.; Castell, J.V.; O’Connor, J.E. A human hepatocellular in vitro model to investigate steatosis. Chem. Interact. 2007, 165, 106–116. [Google Scholar] [CrossRef]
- Ricchi, M.; Odoardi, M.R.; Carulli, L.; Anzivino, C.; Ballestri, S.; Pinetti, A.; Fantoni, L.I.; Marra, F.; Bertolotti, M.; Banni, S.; et al. Differential effect of oleic and palmitic acid on lipid accumulation and apoptosis in cultured hepatocytes. J. Gastroenterol. Hepatol. 2009, 24, 830–840. [Google Scholar] [CrossRef] [PubMed]
- Chiappini, F.; Coilly, A.; Kadar, H.; Gual, P.; Tran, A.; Desterke, C.; Samuel, D.; Duclos-Vallée, J.C.; Touboul, D.; Bertrand-Michel, J.; et al. Metabolism dysregulation induces a specific lipid signature of nonalcoholic steatohepatitis in patients. Sci. Rep. 2017, 7, 46658. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Palladini, G.; Di Pasqua, L.G.; Berardo, C.; Siciliano, V.; Richelmi, P.; Mannucci, B.; Croce, A.C.; Rizzo, V.; Perlini, S.; Vairetti, M.; et al. Fatty Acid Desaturase Involvement in Non-Alcoholic Fatty Liver Disease Rat Models: Oxidative Stress versus Metalloproteinases. Nutrients 2019, 11, 799. [Google Scholar] [CrossRef] [PubMed]
- Puri, P.; Wiest, M.M.; Cheung, O.; Mirshahi, F.; Sargeant, C.; Min, H.K.; Contos, M.J.; Sterling, R.K.; Fuchs, M.; Zhou, H.; et al. The Plasma Lipidomic Signature of Nonalcoholic Steatohepatitis. Hepatology 2009, 50, 1827–1838. [Google Scholar] [CrossRef] [PubMed]
- Hudgins, L.C.; Hellerstein, M.; Seidman, C.; Neese, R.; Diakun, J.; Hirsch, J. Human fatty acid synthesis is stimulated by a eucaloric low fat, high carbohydrate diet. J. Clin. Investig. 1996, 97, 2081–2091. [Google Scholar] [CrossRef] [PubMed]
- Paglialunga, S.; Dehn, C.A. Clinical assessment of hepatic de novo lipogenesis in non-alcoholic fatty liver disease. Lipids Health Dis. 2016, 15, 686. [Google Scholar] [CrossRef] [PubMed]
- Hirst, S.M.; Karakoti, A.S.; Tyler, R.D.; Sriranganathan, N.; Seal, S.; Reilly, C.M. Anti-inflammatory Properties of Cerium Oxide Nanoparticles. Small 2009, 5, 2848–2856. [Google Scholar] [CrossRef]
- Gaiser, B.K.; Fernandes, T.F.; Jepson, M.A.; Lead, J.R.; Tyler, C.R.; Baalousha, M.; Biswas, A.; Britton, G.J.; Cole, P.A.; Johnston, B.D.; et al. Interspecies comparisons on the uptake and toxicity of silver and cerium dioxide nanoparticles. Environ. Toxicol. Chem. 2012, 31, 144–154. [Google Scholar] [CrossRef] [PubMed]
- Singh, R.; Singh, S. Redox-dependent catalase mimetic cerium oxide-based nanozyme protect human hepatic cells from 3-AT induced acatalasemia. Colloids Surf. B Biointerfaces 2019, 175, 625–635. [Google Scholar] [CrossRef]
- Salomone, F.; Godos, J.; Zelber-Sagi, S. Natural antioxidants for non-alcoholic fatty liver disease: Molecular targets and clinical perspectives. Liver Int. 2016, 36, 5–20. [Google Scholar] [CrossRef]
- Rolo, A.P.; Teodoro, J.S.; Palmeira, C.M. Role of oxidative stress in the pathogenesis of nonalcoholic steatohepatitis. Free Radic. Biol. Med. 2012, 52, 59–69. [Google Scholar] [CrossRef] [PubMed]
- Azari, A.; Shokrzadeh, M.; Zamani, E.; Amani, N.; Shaki, F. Cerium oxide nanoparticles protects against acrylamide induced toxicity in HepG2 cells through modulation of oxidative stress. Drug. Chem. Toxicol. 2019, 42, 54–59. [Google Scholar] [CrossRef] [PubMed]
- Serviddio, G.; Bellanti, F.; Villani, R.; Tamborra, R.; Zerbinati, C.; Blonda, M.; Ciacciarelli, M.; Poli, G.; Vendemiale, G.; Iuliano, L. Effects of dietary fatty acids and cholesterol excess on liver injury: A lipidomic approach. Redox Biol. 2016, 9, 296–305. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Corominas, M.P.; Carvajal, S.; Oró, D.; Casals, E.; Varo, G.F.; Casals, G.; Parra-Robert, M.; Ribera, J.; Morales-Ruiz, M.; Puntes, V.; et al. FRI-334-Cerium oxide nanoparticles present antilipogenic and antiinflammatory effects in rats with diet-induced non-alcoholic fatty liver disease. J. Hepatol. 2019, 70, e543. [Google Scholar] [CrossRef]
- Kitchin, K.T.; Grulke, E.; Robinette, B.L.; Castellon, B.T. Metabolomic effects in HepG2 cells exposed to four TiO2 and two CeO2 nanomaterials. Environ. Sci. Nano 2014, 1, 466–477. [Google Scholar] [CrossRef]
- Kitchin, K.T.; Stirdivant, S.; Robinette, B.L.; Castellon, B.T.; Liang, X. Metabolomic effects of CeO2, SiO2 and CuO metal oxide nanomaterials on HepG2 cells. Part Fibre Toxicol. 2017, 14, 50. [Google Scholar] [CrossRef] [PubMed]
- Sun, H.; Yang, W.; Tian, Y.; Zeng, X.; Zhou, J.; Mok, M.T.S.; Tang, W.; Feng, Y.; Xu, L.; Chan, A.W.H.; et al. An inflammatory-CCRK circuitry drives mTORC1-dependent metabolic and immunosuppressive reprogramming in obesity-associated hepatocellular carcinoma. Nat. Commun. 2018, 9, 5214. [Google Scholar] [CrossRef] [PubMed]
- Ansari, A.; Bose, S.; Patra, J.K.; Shin, N.R.; Lim, D.W.; Kim, K.W.; Wang, J.H.; Kim, Y.M.; Chin, Y.W.; Kim, H. A Controlled Fermented Samjunghwan Herbal Formula Ameliorates Non-alcoholic Hepatosteatosis in HepG2 Cells and OLETF Rats. Front. Pharmacol. 2018, 9, 596. [Google Scholar] [CrossRef]
- Araya, J.; Rodrigo, R.; Videla, L.A.; Thielemann, L.; Orellana, M.; Pettinelli, P.; Poniachik, J. Increase in long-chain polyunsaturated fatty acid n−6/n−3 ratio in relation to hepatic steatosis in patients with non-alcoholic fatty liver disease. Clin. Sci. 2004, 106, 635–643. [Google Scholar] [CrossRef]
- Baylin, A.; Kabagambe, E.K.; Siles, X.; Campos, H. Adipose tissue biomarkers of fatty acid intake. Am. J. Clin. Nutr. 2002, 76, 750–757. [Google Scholar] [CrossRef] [Green Version]
- Yamada, K.; Mizukoshi, E.; Sunagozaka, H.; Arai, K.; Yamashita, T.; Takeshita, Y.; Misu, H.; Takamura, T.; Kitamura, S.; Zen, Y.; et al. Characteristics of hepatic fatty acid compositions in patients with nonalcoholic steatohepatitis. Liver Int. 2015, 35, 582–590. [Google Scholar] [CrossRef] [PubMed]
- Puri, P.; Baillie, R.A.; Wiest, M.M.; Mirshahi, F.; Choudhury, J.; Cheung, O.; Sargeant, C.; Contos, M.J.; Sanyal, A.J. A lipidomic analysis of nonalcoholic fatty liver disease. Hepatology 2007, 46, 1081–1090. [Google Scholar] [CrossRef] [PubMed]
- Kotronen, A.; Seppänen-Laakso, T.; Westerbacka, J.; Kiviluoto, T.; Arola, J.; Ruskeepää, A.L.; Orešič, M.; Yki-Järvinen, H. Hepatic steatoyl-CoA desaturase (SCD)-1 activity and diacylglycerol but not ceramide concentrations are increased in the nonalcoholic human fatty liver. Diabetes 2009, 58, 203–208. [Google Scholar] [CrossRef] [PubMed]
- Wang, X.; Cao, Y.; Fu, Y.; Guo, G.; Zhang, X. Liver fatty acid composition in mice with or without nonalcoholic fatty liver disease. Lipids Health Dis. 2011, 10, 234. [Google Scholar] [CrossRef] [PubMed]
- Ma, C.; Kesarwala, A.H.; Eggert, T.; Medina-Echeverz, J.; Kleiner, D.E.; Jin, P.; Stroncek, D.F.; Terabe, M.; Kapoor, V.; ElGindi, M.; et al. NAFLD causes selective CD4(+) T lymphocyte loss and promotes hepatocarcinogenesis. Nature 2016, 531, 253–257. [Google Scholar] [CrossRef] [PubMed]
- Ballestri, S.; Nascimbeni, F.; Romagnoli, D.; Baldelli, E.; Lonardo, A. The Role of Nuclear Receptors in the Pathophysiology, Natural Course, and Drug Treatment of NAFLD in Humans. Adv. Ther. 2016, 33, 291–319. [Google Scholar] [CrossRef] [PubMed]
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Parra-Robert, M.; Casals, E.; Massana, N.; Zeng, M.; Perramón, M.; Fernández-Varo, G.; Morales-Ruiz, M.; Puntes, V.; Jiménez, W.; Casals, G. Beyond the Scavenging of Reactive Oxygen Species (ROS): Direct Effect of Cerium Oxide Nanoparticles in Reducing Fatty Acids Content in an In Vitro Model of Hepatocellular Steatosis. Biomolecules 2019, 9, 425. https://doi.org/10.3390/biom9090425
Parra-Robert M, Casals E, Massana N, Zeng M, Perramón M, Fernández-Varo G, Morales-Ruiz M, Puntes V, Jiménez W, Casals G. Beyond the Scavenging of Reactive Oxygen Species (ROS): Direct Effect of Cerium Oxide Nanoparticles in Reducing Fatty Acids Content in an In Vitro Model of Hepatocellular Steatosis. Biomolecules. 2019; 9(9):425. https://doi.org/10.3390/biom9090425
Chicago/Turabian StyleParra-Robert, Marina, Eudald Casals, Nuria Massana, Muling Zeng, Meritxell Perramón, Guillermo Fernández-Varo, Manuel Morales-Ruiz, Víctor Puntes, Wladimiro Jiménez, and Gregori Casals. 2019. "Beyond the Scavenging of Reactive Oxygen Species (ROS): Direct Effect of Cerium Oxide Nanoparticles in Reducing Fatty Acids Content in an In Vitro Model of Hepatocellular Steatosis" Biomolecules 9, no. 9: 425. https://doi.org/10.3390/biom9090425